DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.

Author(s): Abraham L(1), Pinkerton JV(2), Messig M(3), Ryan KA(4), Komm BS(5), Mirkin S(6).

Affiliation(s): Author information: (1)Pfizer Ltd., Dorking Road, Tadworth, Kent KT20 7NS, UK. Electronic address: Lucy.Abraham@pfizer.com. (2)Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22903, USA. Electronic address: jvp9u@virginia.edu. (3)Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Michael.Messig@pfizer.com. (4)Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Kelly.A.Ryan@pfizer.com. (5)Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Barry.Komm@pfizer.com. (6)Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Mirkin.Sebastian@gmail.com.

Publication date & source: 2014, Maturitas. , 78(3):212-8

OBJECTIVE: Describe the effects of conjugated estrogens/bazedoxifene (CE/BZA), a new treatment for vasomotor symptoms (VMS) and osteoporosis prevention, on menopause-specific quality of life (MSQOL) across different patient population types in phase 3 clinical trials. DESIGN: MSQOL was prospectively evaluated in 4 randomized, double-blind, placebo-controlled studies. The populations studied included healthy, non-hysterectomized postmenopausal women with symptomatic VMS or vulvar-vaginal atrophy (VVA) and general postmenopausal women (eligible regardless of symptoms). Menopause-specific Quality of Life (MENQOL) questionnaire total and domain scores for CE 0.625 mg/BZA 20mg and CE 0.45 mg/BZA 20mg were evaluated and compared with established thresholds for clinically important differences (CID). RESULTS: Significant improvements compared with placebo were found with both CE/BZA doses in MENQOL vasomotor domain (-0.61 to -2.23 over 3-24 months) and total scores (-0.24 to -0.94) in the general and symptomatic VMS/VVA populations. Significant improvement compared with placebo in sexual domain (-0.11 to -0.72) was observed with the higher dosage for all populations, and with the lower dosage in the VVA (-0.71 at month 3) and general populations (-0.4 at months 12 and 24). Improvements in vasomotor domain exceeded the CID with both doses in symptomatic VMS populations and with the higher dosage in women with symptomatic VVA; for total MENQOL, the CID was exceeded with the higher dose in symptomatic VMS populations. CONCLUSIONS: CE/BZA significantly improved overall and vasomotor-related MSQOL across populations of postmenopausal women with varying baseline symptom statuses. Women with greater menopausal symptoms at baseline were more likely to experience clinically meaningful changes.

Erratum in Maturitas. 2014 Dec;79(4):488.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017